Scientists at Cambridge University say they have seen four-stranded DNA at work in human cells for the first time. The molecule is more familiar to us as a double helix, but researchers tell the journal Nature Chemistry that the "quadruple helix" is also present in our cells. The incidence of this type of DNA has been observed before when it was identified in ciliates, relatively small microscopic organisms, but the new research is said to be the first to firmly pinpoint the quadruple helix in human cells. The researchers also believe that the four-stranded DNA molecule may be present in ways that could possibly relate to cancer, and if so, having control over these structures would provide novel ways to fight the disease.
Prof Shankar Balasubramanian, from Cambridge's department of Chemistry, said "The existence of these structures may be loaded when the cell has a certain genotype or a certain dysfunctional state", and also commented: "We need to prove that; but if that is the case, targeting them with synthetic molecules could be an interesting way of selectively targeting those cells that have this dysfunction."
This February it will be exactly 60 years since James Watson and Francis Crick famously burst into the pub next to their Cambridge laboratory to announce their discovery of "the secret of life". Their achievement was being able to describe the way in which two long chemical chains wound up around each other, in order to encode the information needed by cells to build and maintain our bodies; today scientists at Cambridge continue to work on DNA's complexities.
Balasubramanian's group has been pursuing a four-stranded version of the molecule, that scientists have been able to produce in the test tube for a number of years. It's called the G-quadruplex, with the "G" referring to guanine, one of the four bases that can be found in DNA. It seems to form in DNA where the guanine base exists in substantial quantities.
The team, led by Giulia Biffi, a researcher in Balasubramanian's lab, created antibody proteins that were specifically designed to track down and bind to regions of human DNA that were rich in the quadruplex structure. They were tagged with a fluorescence marker so that the time and place of the structures' emergence in the cell cycle could be noted and imaged. This revealed that the four-stranded DNA arose most frequently during the s-phase of mitosis, in which DNA is copied just prior to dividing.
Prof Balasubramanian said that, if the G-quadruplex could be implicated in the development of some cancers, it may be possible to make synthetic molecules that contained the structure and blocked the runaway cell proliferation at the root of tumours. He went on to say: "I'm hoping now that the pharmaceutical companies will bring this on to their radar and we can perhaps take a more serious look at whether quadruplexes are indeed therapeutically viable targets."
Jack
Saturday, 26 January 2013
Saturday, 19 January 2013
Early HIV drugs slow virus down
Researchers say that giving drugs to a HIV patient as soon as they are diagnosed could be the future of treatment. Currently, antiretroviral therapy is only given once the immune system has been seriously weakened by infection, but it is very important for the patient to keep a strong immune system in order to prevent other "opportunistic" infections from taking hold.
The HIV virus is no longer a death sentence for patients who get the best care and treatment. Treatment is given once their CD4 T-cell count falls below 350 cells per cubic millimetre of blood, but there has been speculation that beginning the therapy as soon as the patient has been diagnosed may be more beneficial.
A trial, published in the New England Journal of Medicine, showed that a year-long course of therapy given after diagnosis helped to preserve the immune system and keep the virus in check; it is also thought that early treatment may reduce the spread of HIV. In the study, which involved 366 patients from eight countries around the world, one group of patients was given 12 weeks of drugs after being diagnosed and another received drugs for 48 weeks after diagnosis. There was also a third group and these patients were given no drugs until they reached the 350 level, which is the current practice and was used as the control group in the experiment.
Professor Jonathan Weber, from Imperial College London, said the patients on the 48-week regime "ended up with a much higher CD4 cell count and a much lower viral load." He also added that the benefits of the drugs persist after the treatment has been stopped. As well as this Dr Sarah Fidler, also from Imperial, pointed out that this could be very important in helping to reduce the risk of passing on the virus to a sexual partner. However Prof. Weber also acknowledged that the cost would represent "a real problem" in poorer parts of the world, and in richer countries it would only mean "a few extra years" on a lifetime of medication.
Nevertheless one of the biggest problems concerning HIV remains identifying people who have been infected; in the UK one in four people who have HIV are thought to be completely unaware they have the infection. Therefore it is also important to raise awareness and provide adequate screening for people who may have the virus.
Jack
The HIV virus is no longer a death sentence for patients who get the best care and treatment. Treatment is given once their CD4 T-cell count falls below 350 cells per cubic millimetre of blood, but there has been speculation that beginning the therapy as soon as the patient has been diagnosed may be more beneficial.
A trial, published in the New England Journal of Medicine, showed that a year-long course of therapy given after diagnosis helped to preserve the immune system and keep the virus in check; it is also thought that early treatment may reduce the spread of HIV. In the study, which involved 366 patients from eight countries around the world, one group of patients was given 12 weeks of drugs after being diagnosed and another received drugs for 48 weeks after diagnosis. There was also a third group and these patients were given no drugs until they reached the 350 level, which is the current practice and was used as the control group in the experiment.
Professor Jonathan Weber, from Imperial College London, said the patients on the 48-week regime "ended up with a much higher CD4 cell count and a much lower viral load." He also added that the benefits of the drugs persist after the treatment has been stopped. As well as this Dr Sarah Fidler, also from Imperial, pointed out that this could be very important in helping to reduce the risk of passing on the virus to a sexual partner. However Prof. Weber also acknowledged that the cost would represent "a real problem" in poorer parts of the world, and in richer countries it would only mean "a few extra years" on a lifetime of medication.
Nevertheless one of the biggest problems concerning HIV remains identifying people who have been infected; in the UK one in four people who have HIV are thought to be completely unaware they have the infection. Therefore it is also important to raise awareness and provide adequate screening for people who may have the virus.
Jack
Saturday, 12 January 2013
Sickle-shaped erythrocytes fight cancer
Research in the journal Plos One shows that misshapen red blood cells could be used as a tool to kill cancer cells, according to experiments carried out on mice. The researchers involved say that sickle-shaped cells can stick together in blood vessels surrounding tumours, blocking blood flow to the cancer. The blood cells are also able to deposit toxic residues on the tumour, leading to the death of the cancer cells. The research in question focused on the oxygen-poor areas of tumours, which have proven difficult to treat in humans.
The US researchers from Duke University and Jenomic, a private research company, gave mice with cancer a fluorescent sickle-cell solution and observed what happened within their systems. Prof. Mark Dewhirst from Duke University, who was co-author of the study, said that in less than five minutes the misshapen cells had begun to stick like 'Velcro' to blood vessels near oxygen-starved areas of the tumour. At 30 minutes the cells began to form clots and block the small blood vessels which fed the tumour, once this had happened they then deposited the toxic residue which killed the tumour cells. An additional bonus is that the sickle-shaped cells exclusively targeted the oxygen-low areas of the tumour, which can become increasingly aggressive forms of cancer in humans.
The sickle cells used in the study are the exact same type that can be found in people with sickle-cell anaemia, which unlike normal erythrocytes are crescent-moon shaped and can clump together in blood vessels rather than flowing through smoothly. Dr David Terman, another co-author of the study and head of molecular genetics at Jenomic said: "The very qualities that make sickle cells a danger to people with the inherited genetic disorder can be turned against tumours to fight cancer."
This is an intriguing new tactic for destroying tumours that are resistant to standard treatments, but as with all therapies tested on mice the next challenge is to determine whether they are safe and effective in humans. The researchers say that the approach could be directed at breast cancers, prostate cancers and many other tumours that develop resistance to current therapies, once more animal studies and human trials have been conducted.
Jack
The US researchers from Duke University and Jenomic, a private research company, gave mice with cancer a fluorescent sickle-cell solution and observed what happened within their systems. Prof. Mark Dewhirst from Duke University, who was co-author of the study, said that in less than five minutes the misshapen cells had begun to stick like 'Velcro' to blood vessels near oxygen-starved areas of the tumour. At 30 minutes the cells began to form clots and block the small blood vessels which fed the tumour, once this had happened they then deposited the toxic residue which killed the tumour cells. An additional bonus is that the sickle-shaped cells exclusively targeted the oxygen-low areas of the tumour, which can become increasingly aggressive forms of cancer in humans.
The sickle cells used in the study are the exact same type that can be found in people with sickle-cell anaemia, which unlike normal erythrocytes are crescent-moon shaped and can clump together in blood vessels rather than flowing through smoothly. Dr David Terman, another co-author of the study and head of molecular genetics at Jenomic said: "The very qualities that make sickle cells a danger to people with the inherited genetic disorder can be turned against tumours to fight cancer."
This is an intriguing new tactic for destroying tumours that are resistant to standard treatments, but as with all therapies tested on mice the next challenge is to determine whether they are safe and effective in humans. The researchers say that the approach could be directed at breast cancers, prostate cancers and many other tumours that develop resistance to current therapies, once more animal studies and human trials have been conducted.
Jack
Friday, 4 January 2013
Immune system boost hits cancer and HIV
Vast numbers of cells that are able to attack cancer and HIV have been grown in a lab, and could potentially be used to fight disease. Naturally the cells occur in small numbers, but it is hoped that injecting huge quantities back into a patient could turbo-charge the immune system.
Experts said the results showed exciting potential, but any therapy would need to be shown to be safe before it could be used.
In the study the researchers concentrated on a type of white blood cell known as a cytotoxic T-cell, which is able to recognise signs of infection or cancer on cell membranes. If one is recognised, it then launches an attack against that cell.
They created large amounts of T-cells by first extracting a sample from the patient and then converting them into stem cells; they then allowed them to multiply in the laboratory before turning them back into T-cells.
It does not mean however that they can be safely put back into patients, or that they would have any significant effects if they did, they merely discovered that it is possible to make the cells. Dr Hiroshi Kawamoto, who worked on the immune cells at the Riken Research Centre for Allergy and Immunology, said: "The next step will be to test whether these T-cells can selectively kill tumour cells, but not other cells in the body."
Other experts said the findings were still at an early stage, but were still very promising and represented a strong foundation for future research. Cancer Research UK however said it was still too early to know if any resulting therapy would be safe.
Jack
Experts said the results showed exciting potential, but any therapy would need to be shown to be safe before it could be used.
In the study the researchers concentrated on a type of white blood cell known as a cytotoxic T-cell, which is able to recognise signs of infection or cancer on cell membranes. If one is recognised, it then launches an attack against that cell.
They created large amounts of T-cells by first extracting a sample from the patient and then converting them into stem cells; they then allowed them to multiply in the laboratory before turning them back into T-cells.
It does not mean however that they can be safely put back into patients, or that they would have any significant effects if they did, they merely discovered that it is possible to make the cells. Dr Hiroshi Kawamoto, who worked on the immune cells at the Riken Research Centre for Allergy and Immunology, said: "The next step will be to test whether these T-cells can selectively kill tumour cells, but not other cells in the body."
Other experts said the findings were still at an early stage, but were still very promising and represented a strong foundation for future research. Cancer Research UK however said it was still too early to know if any resulting therapy would be safe.
Jack
Subscribe to:
Posts (Atom)
